α-突触核蛋白对THP-1巨噬细胞源性泡沫细胞胆固醇蓄积和LOX-1表达的影响

doi:10.20223/j.cnki.1000-8535.2026.02.007

摘要/Abstract

摘要： 目的探索α-突触核蛋白（α-Syn）干预对人单核细胞白血病细胞系（THP-1）巨噬细胞源性泡沫细胞的影响。方法通过佛波酯（PMA）和氧化型低密度脂蛋白（ox-LDL）构建THP-1巨噬细胞源性泡沫细胞模型,使用不同浓度（33、66、100、133 nmol/L）α-Syn处理泡沫细胞,随后检测细胞胆固醇含量和炎症因子白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）及白细胞介素-8（IL-8）的mRNA表达以及核因子κB（NF-κB）和凝集素样氧化低密度脂蛋白受体-1（LOX-1）的蛋白表达变化。结果高剂量（100和133 nmol/L）α-Syn处理可以减少THP-1巨噬细胞源性泡沫细胞内胆固醇的含量（P<0.05）,并且减少IL-1β、IL-6和IL-8的mRNA表达（P<0.05）。进一步发现（100 nmol/L和133 nmol/L）α-Syn可以降低THP-1巨噬细胞源性泡沫细胞p-NF-κB和LOX-1的蛋白表达（P<0.05）。结论 α-Syn可以降低THP-1源性巨噬细胞泡沫细胞胆固醇蓄积和炎症反应,可能是通过下调p-NF-κB和LOX-1蛋白表达。

关键词: α-突触核蛋白, 人单核细胞白血病细胞系巨噬细胞源性泡沫细胞, 胆固醇, 炎症

Abstract: Objective To explore the effects of α-synuclein（α-Syn）intervention on human monocytic leukemia cell（THP-1）macrophage-derived foam cells．Methods The THP-1 macrophage-derived foam cell model was constructed by phorbol 12-myristate 13-acetate（PMA）and oxidized low-density lipoprotein（ox-LDL）．Foam cells were treated with different concentrations（33,66,100,and 133 nmol/L）of α-Syn,and the cellular cholesterol contents,as well as the mRNA expression of IL-1β、IL-6 and IL-8 were detected．Subsequently,alternation in protein expression of NF-κB and LOX-1 was measured．Results High-dose（100 and 133nmol/L）α-Syn treatment significantly reduced the levels of intracellular cholesterol in THP-1-derived macrophage foam cells（P<0.05）and decreased the mRNA expression of IL-1β、IL-6 and IL-8（P<0.05）．It was further found that（100 nmol/L and 133 nmol/L）α-Syn decreased the protein expression of p-NF-κB and LOX-1 in THP-1 macrophage-derived foam cells（P<0.05）．Conclusions The results of the present study suggest that α-Syn reduces cholesterol accumulation and inflammatory response in THP-1-derived macrophage foam cells,possibly by down-regulating p-NF-κB and LOX-1 protein expression．

Key words: α-synuclein, THP-1 macrophage-derived foam cells, cholesterol, inflammation

吴向斌, 夏忠斌, 桂敏, 谈丹丹, 柴竞艳, 官燕琴, 鲍兵, 陈志颖. α-突触核蛋白对THP-1巨噬细胞源性泡沫细胞胆固醇蓄积和LOX-1表达的影响[J]. 广州医药, 2026, 57(2): 176-181.

WU Xiangbin, XIA Zhongbin, GUI Min, TAN Dandan, CHAI Jingyan, GUAN Yanqing, BAO bing, CHEN Zhiying. Effects of α-synuclein on cholesterol accumulation and LOX-1 expression in THP-1 macrophage-derived foam cells[J]. Guangzhou Medical Journal, 2026, 57(2): 176-181.

参考文献

[1] FERENCE B A,BRAUNWALD E,CATAPANO A L.The LDL cumulative exposure hypothesis:Evidence and practical applications[J].Nat Rev Cardiol,2024,21(10):701-716.
[2] LA CHICA L M,MARTINEZ A,CLAUDI L,et al.Mechanisms modulating foam cell formation in the arterial intima:Exploring new therapeutic opportunities in atherosclerosis[J].Front Cardiovasc Med,2024(11):1381520.
[3] SORCI-THOMAS M G,THOMAS M J.Microdomains,inflammation,and atherosclerosis[J].Circ Res,2016,118(4):679-691.
[4] WANG K,ZHOU W,HU G,et al.TFEB SUMOylation in macrophages accelerates atherosclerosis by promoting the formation of foam cells through inhibiting lysosomal activity[J].Cell Mol Life Sci,2023,80(12):358.
[5] ZHOU Z,ZHANG M,FANG Q,et al.Relationship between Parkinson's disease and cardio-cerebrovascular diseases:A Mendelian randomized study[J].Sci Rep,2023,13(1):20428.
[6] SCHWARTZ R S,HALLIDAY G M,CORDATO D J,et al.Small-vessel disease in patients with Parkinson's disease:A clinicopathological study[J].Mov Disord,2012,27(12):1506-1512.
[7] NANHOE-MAHABIER W,de LAAT K F,VISSER J E,et al.Parkinson disease and comorbid cerebrovascular disease[J].Nat Rev Neurol,2009,5(10):533-541.
[8] 杨旭,柳华,马英,等.血脂与帕金森病相关性研究[J].西部医学,2014,26(6):725-727.
[9] BURRE J,EDWARDS R H,HALLIDAY G,et al.Research priorities on the role of α-synuclein in Parkinson's disease pathogenesis[J].Mov Disord,2024,39(10):1663-1678.
[10] DRIVER-DUNCKLEY E D,ZHANG N,ADLER C H,et al.Brain lewy-type synucleinopathy density is associated with a lower prevalence of atherosclerotic cardiovascular disease risk factors in patients with Parkinson's disease1[J].J Parkinsons Dis,2019,9(3):543-552.
[11] EMAMZADEH F N,ALLSOP D.α-synuclein interacts with lipoproteins in plasma[J].J Mol Neurosci,2017,63(2):165-172.
[12] CHO K H.Structural and functional changes of reconstituted high-density lipoprotein(HDL) by Incorporation of α-synuclein:A potent antioxidant and anti-glycation activity of α-synuclein and apoA-I in HDL at high molar ratio of α-synuclein[J].Molecules,2021,26(24):7485.
[13] EICHMANN C,KUMARI P,RIEK R.High-density lipoprotein-like particle formation of Synuclein variants[J].FEBS Lett,2017,591(2):304-311.
[14] WANG C,ZHANG K,CAI B,et al.VAMP2 chaperones α-synuclein in synaptic vesicle co-condensates[J].Nat Cell Biol,2024,26(8):1287-1295.
[15] ZHAO C,TU J,WANG C,et al.Lysophosphatidylcholine binds α-synuclein and prevents its pathological aggregation[J].Natl Sci Rev,2024,11(6):nwae182.
[16] LIBBY P.The changing landscape of atherosclerosis[J].Nature,2021,592(7855):524-533.
[17] HE Z,CHEN W,HU K,et al.Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment[J].Nat Nanotechnol,2024,19(9):1386-1398.
[18] HUANGZQ,LUOW,LIWX,et al.Costunolidealleviatesatherosclerosisinhigh-fatdiet-fedApoE-/-micethroughcovalentlybinding to IKKβandinhibitingNF-κB-mediatedinflammation[J].Acta Pharmacol Sin,2023,44(1):58-70.
[19] XIAO L,LIU Y,WANG N.New paradigms in inflammatory signaling in vascular endothelial cells[J].Am J Physiol Heart Circ Physiol,2014,306(3):H317-H325.
[20] JIANG H,ZHOU Y,NABAVI S M,et al.Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis[J].Front Cardiovasc Med,2022(9):925923.
[21] SÁNCHEZ-LEÓNME,LOAEZA-REYESKJ,MATIAS-CERVANTESCA,etal.LOX-1incardiovasculardisease:Acomprehensivemolecularandclinicalreview[J].IntJMolSci,2024,25(10):5276.
[22] KATTOOR A J,KANURI S H,MEHTA J L.Role of ox-LDL and LOX-1 in atherogenesis[J].Curr Med Chem,2019,26(9):1693-1700.
[23] TIAN K,OGURA S,LITTLE P J,et al.Targeting LOX-1 in atherosclerosis and vasculopathy:Current knowledge and future perspectives[J].Ann N Y Acad Sci,2019,1443(1):34-53.
[24] GUAN S,WANG B,LI W,et al.Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL[J].Am J Chin Med,2010,38(6):1161-1169.
[25] 朱怡怡,杨婵,王振兴.全身免疫炎症指数与心血管疾病相关研究进展[J].广州医药,2024,55(9):985-990.
[26] 姜泽军,汤胜宇,杨红玲.炎症标志物在慢性心力衰竭临床预后评估中的作用[J].国际医药卫生导报,2025,31(1):42-46.
[27] 谢曦,蔡志友,王启征,等.脑血管病的研究进展[J].国际医药卫生导报,2024,30(13):2114-2118.
[28] ATTIQ A,AFZAL S,AHMAD W,et al.Hegemony of inflammation in atherosclerosis and coronary artery disease[J].Eur J Pharmacol,2024(966):176338.
[29] BIROS E,REZNIK J E,MORAN C S.Role of inflammatory cytokines in genesis and treatment of atherosclerosis[J].Trends Cardiovasc Med,2022,32(3):138-142.